2025 Annual Meeting | C86 - Clinical Pearls in Autoimmune Neurology: Real-world Cases
Program Materials Program Evaluations
07:00 AM - 07:05 AM PDT | Introduction |
Introduction
Sarosh R. Irani, MD, PhD, FRCP, FEAN |
07:05 AM - 07:40 AM PDT | Speaker |
Pearls and Pitfalls in the Diagnosis of Demyelinating Syndromes
Brian G. Weinshenker, MD, FAAN |
07:40 AM - 08:15 AM PDT | Speaker |
Under-recognition and Misdiagnosis in Autoimmune Encephalitis
Sarosh R. Irani, MD, PhD, FRCP, FEAN |
08:15 AM - 08:40 AM PDT | Speaker |
Treatable Immunology from Nerve to Muscle
Christopher Lamb, MD |
08:40 AM - 09:00 AM PDT | Q&A |
Questions and Answers
Sarosh R. Irani, MD, PhD, FRCP, FEAN, Brian G. Weinshenker, MD, FAAN, Christopher Lamb, MD |
Sarosh R. Irani, MD, PhD, FRCP, FEAN | Dr. Irani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for AZ, Roche, Cerebral therapeutics, Biogen, Amgen, Argenex, Clarivate, IQVIA, BioHaven therapeutics.. Dr. Irani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Brain. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. |
Brian G. Weinshenker, MD, FAAN | Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care. |
Christopher Lamb, MD | Dr. Lamb has received research support from Immunovant, Inc. |